AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging AstraZeneca's announcement that its experimental cancer treatment tislelizumab had failed in a late stage clinical trial sent shockwaves through the pharmaceutical industry and financial markets, wiping out approximately 10% of the company's stock value in a single day.
The news was met with widespread disappointment among investors, researchers, and patients who had been counting on this potential new therapy. What Happened in AstraZeneca's Trial?
The failed trial involved tislelizumab, an immunotherapy drug designed to treat non small cell lung cancer (NSCLC) and other solid tumors.